Overview
Sahelian zoonotic cutaneous leishmaniasis (ZCL) is a significant public health concern in regions such as the Sahel, where it is transmitted primarily through the bite of infected sandflies. Unlike anthroponotic forms of leishmaniasis, ZCL is predominantly zoonotic, involving reservoir hosts such as rodents and dogs. The disease manifests as skin lesions that can be disfiguring and debilitating, affecting both humans and animals. Military personnel and their working dogs deployed in endemic areas, such as Vietnam, have historically faced heightened exposure risks, as evidenced by the high seroprevalence observed in these groups. Understanding the epidemiology, diagnosis, and management of ZCL is crucial for effective control and treatment strategies, particularly in vulnerable populations like military scouts and trackers.
Epidemiology
The epidemiology of Sahelian zoonotic cutaneous leishmaniasis highlights significant exposure risks among both humans and animals in endemic regions. Studies conducted among military scout and tracker dogs deployed in Vietnam revealed substantial seroprevalence of zoonotic infections, including leishmaniasis-related conditions [PMID:4564881]. Notably, after seven or more months of service, only three out of 45 dogs failed to develop antibodies to one or more zoonotic agents, underscoring the cumulative exposure risk these animals face in endemic environments. This high seroprevalence suggests that prolonged deployment in areas with active sandfly populations significantly increases the likelihood of infection. The presence of antibodies to multiple zoonotic agents, including leptospirosis, indicates a complex ecological interplay where various pathogens coexist, complicating diagnostic and preventive efforts. In clinical practice, these findings emphasize the need for rigorous surveillance and preventive measures for both human and animal populations in endemic zones.
The transmission dynamics in these regions often involve reservoir hosts such as rodents and dogs, which maintain the parasite cycle independently of human infection. This zoonotic cycle complicates control measures, as interventions must target both the vector (sandflies) and the reservoir hosts to effectively reduce transmission rates. Understanding these epidemiological patterns is essential for tailoring public health strategies that account for the multifaceted nature of ZCL transmission.
Diagnosis
Diagnosing Sahelian zoonotic cutaneous leishmaniasis (ZCL) involves a combination of clinical evaluation and laboratory testing, with serological methods playing a pivotal role, especially in post-exposure scenarios. Paired sera testing has emerged as a valuable diagnostic tool, revealing significant increases in antibody titers for various zoonotic diseases following deployment in endemic areas [PMID:4564881]. This approach not only aids in confirming recent infections but also helps in monitoring the progression and persistence of the disease over time. Serological monitoring can detect both acute and chronic infections, making it particularly useful for military personnel and their working dogs who have been exposed to high-risk environments.
In clinical practice, the initial suspicion of ZCL often arises from the presence of characteristic skin lesions, typically ulcerative or nodular, often located on exposed areas of the body. However, definitive diagnosis frequently requires laboratory confirmation. Techniques such as indirect immunofluorescence assays (IFA) and enzyme-linked immunosorbent assays (ELISA) are commonly employed to detect specific antibodies against Leishmania species. Polymerase chain reaction (PCR) tests can also be utilized to identify the parasite DNA directly from lesion samples, providing a more direct evidence of infection. Given the potential overlap with other zoonotic diseases, comprehensive serological panels that screen for multiple pathogens are advisable to ensure accurate diagnosis and appropriate management.
Diagnostic Approach
Management
The management of Sahelian zoonotic cutaneous leishmaniasis (ZCL) focuses on both symptomatic relief and targeted treatment to eliminate the parasite and prevent complications. Current therapeutic approaches primarily involve antimonial compounds, although the efficacy and tolerability can vary among patients. Glucantime (intravenous or intramuscular pentavalent antimony) and intramuscular pentamidine are commonly prescribed, with treatment duration typically spanning several weeks [PMID:4564881]. However, resistance to these drugs has been reported in some endemic regions, necessitating careful monitoring and potential alternative therapies.
Symptomatic Care
Pharmacological Treatment
Preventive Measures
Key Recommendations
These recommendations aim to mitigate the impact of Sahelian zoonotic cutaneous leishmaniasis through a multifaceted approach encompassing prevention, diagnosis, and treatment, ultimately safeguarding public health in endemic areas.
References
1 Alexander AD, Binn LN, Elisberg B, Husted P, Huxsoll DL, Marshall JD et al.. Zoonotic infections in military scout and tracker dogs in Vietnam. Infection and immunity 1972. link
1 papers cited of 3 indexed.